- Home
- TYGO vs NGEN Comparison
TYGO vs NGEN Comparison
Compare TYGO & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TYGO | NGEN |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.1M | 314.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TYGO | NGEN |
|---|---|---|
| Price | $3.97 | $3.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 728.5K | 151.8K |
| Earning Date | 05-05-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.12 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $103,536,000.00 | N/A |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $21.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.68 | N/A |
| 52 Week Low | $0.91 | $3.51 |
| 52 Week High | $5.33 | $5.93 |
Technical Indicators
Market Signals| Indicator | TYGO | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.55 | 40.76 |
| Support Level | $3.24 | $3.59 |
| Resistance Level | $4.33 | $4.44 |
| Average True Range (ATR) | 0.47 | 0.20 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 16.91 | 12.37 |
Price Performance
Historical ComparisonAbout TYGO Tigo Energy Inc.
Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.